This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Exemestane

Read time: 1 mins
Marketing start date: 28 Dec 2024

Summary of product characteristics


Effective Time

20220826

Version

5

Spl Product Data Elements

Exemestane Exemestane EXEMESTANE EXEMESTANE HYPROMELLOSES MAGNESIUM CARBONATE MAGNESIUM STEARATE MANNITOL CELLULOSE, MICROCRYSTALLINE POLYSORBATE 80 SODIUM STARCH GLYCOLATE TYPE A POTATO TITANIUM DIOXIDE SILICON DIOXIDE CROSPOVIDONE POLYETHYLENE GLYCOL 300 WHITE ROUND 383

Application Number

ANDA202602

Brand Name

Exemestane

Generic Name

Exemestane

Product Ndc

70771-1374

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1374-3 in bottle of 30 tablets Exemestane Tablets, 25 mg R x only 30 tablets Exemestane Tablets, 25 mg

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.